1999年至2006年期间获得的11种抗菌药物对侵袭性耐甲氧西林金黄色葡萄球菌分离株的抑制活性以及万古霉素和达托霉素的杀菌活性。
Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.
作者信息
Holmes Robert L, Jorgensen James H
机构信息
Infectious Disease Service, Brooke Army Medical Center, Fort San Houston, Texas 78234, USA.
出版信息
Antimicrob Agents Chemother. 2008 Feb;52(2):757-60. doi: 10.1128/AAC.00945-07. Epub 2007 Nov 26.
Abstract
We assessed MICs and minimal bactericidal concentrations of vancomycin, daptomycin, and nine other antimicrobials against methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. No vancomycin, daptomycin, or linezolid resistance was observed. Clindamycin, gentamicin, and ciprofloxacin resistance decreased significantly. No tolerance to vancomycin or daptomycin was observed, nor was MIC creep seen.
摘要
我们评估了万古霉素、达托霉素及其他九种抗菌药物对1999年至2006年期间分离出的耐甲氧西林金黄色葡萄球菌菌株的最低抑菌浓度（MIC）和最低杀菌浓度。未观察到对万古霉素、达托霉素或利奈唑胺的耐药情况。克林霉素、庆大霉素和环丙沙星的耐药性显著下降。未观察到对万古古大霉素或达托霉素的耐受性，也未出现MIC值缓慢升高的情况。
相似文献
1
Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.
Antimicrob Agents Chemother. 2008 Feb;52(2):757-60. doi: 10.1128/AAC.00945-07. Epub 2007 Nov 26.
2
Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):437-40. doi: 10.1016/j.diagmicrobio.2007.11.002. Epub 2007 Dec 21.
3
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Chemother. 2007 Oct;60(4):788-94. doi: 10.1093/jac/dkm258. Epub 2007 Jul 10.
4
Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Diagn Microbiol Infect Dis. 2010 Apr;66(4):441-4. doi: 10.1016/j.diagmicrobio.2009.11.008.
5
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
Clin Microbiol Infect. 2008 Aug;14(8):766-77. doi: 10.1111/j.1469-0691.2008.02035.x.
6
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
J Clin Microbiol. 2008 Mar;46(3):1132-6. doi: 10.1128/JCM.01844-07. Epub 2008 Jan 16.
7
Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.
Antimicrob Agents Chemother. 2009 May;53(5):1735-8. doi: 10.1128/AAC.01022-08. Epub 2009 Feb 17.
8
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Aug;52(8):2974-6. doi: 10.1128/AAC.00257-08. Epub 2008 Jun 2.
9
Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
BMC Infect Dis. 2020 Jan 23;20(1):74. doi: 10.1186/s12879-020-4782-9.
10
[Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].
Enferm Infecc Microbiol Clin. 2010 Jan;28(1):13-6. doi: 10.1016/j.eimc.2008.09.012. Epub 2009 May 5.
引用本文的文献
1
Antibiotic Prophylaxis in One-Stage Revision of Septic Total Knee Arthroplasty: A Scoping Review.
Antibiotics (Basel). 2023 Mar 18;12(3):606. doi: 10.3390/antibiotics12030606.
2
Transcriptomics and systems biology identify non-antibiotic drugs for the treatment of ocular bacterial infection.
iScience. 2022 Aug 2;25(9):104862. doi: 10.1016/j.isci.2022.104862. eCollection 2022 Sep 16.
3
Lyophilized Human Bone Allograft as an Antibiotic Carrier: An In Vitro and In Vivo Study.
Antibiotics (Basel). 2022 Jul 19;11(7):969. doi: 10.3390/antibiotics11070969.
4
The role of reactive oxygen species in the antimicrobial activity of pyochelin.
J Adv Res. 2017 Jul;8(4):393-398. doi: 10.1016/j.jare.2017.05.007. Epub 2017 May 21.
5
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14.
6
Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening.
PLoS One. 2015 Mar 20;10(3):e0118791. doi: 10.1371/journal.pone.0118791. eCollection 2015.
7
Characterization of high-level daptomycin resistance in Viridans group Streptococci developed upon in vitro exposure to daptomycin.
Antimicrob Agents Chemother. 2015 Apr;59(4):2102-12. doi: 10.1128/AAC.04219-14. Epub 2015 Jan 26.
8
Coagulase-negative staphylococci.
Clin Microbiol Rev. 2014 Oct;27(4):870-926. doi: 10.1128/CMR.00109-13.
9
Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid.
J Clin Microbiol. 2014 Jun;52(6):2216-22. doi: 10.1128/JCM.00957-14. Epub 2014 Apr 9.
10
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?
Clin Infect Dis. 2013 Jun;56(12):1779-88. doi: 10.1093/cid/cit178. Epub 2013 Mar 19.
本文引用的文献
1
Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
J Antimicrob Chemother. 2007 Oct;60(4):788-94. doi: 10.1093/jac/dkm258. Epub 2007 Jul 10.
2
Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections.
Emerg Infect Dis. 2007 Feb;13(2):236-42. doi: 10.3201/eid1302.060781.
3
A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
J Clin Microbiol. 2007 Feb;45(2):329-32. doi: 10.1128/JCM.01508-06. Epub 2006 Nov 15.
4
High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Arch Intern Med. 2006 Oct 23;166(19):2138-44. doi: 10.1001/archinte.166.19.2138.
5
Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.
J Clin Microbiol. 2006 Nov;44(11):3883-6. doi: 10.1128/JCM.01388-06. Epub 2006 Sep 6.
6
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
Antimicrob Agents Chemother. 2006 Sep;50(9):3039-47. doi: 10.1128/AAC.00422-06.
7
The role of vancomycin in the treatment paradigm.
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S51-7. doi: 10.1086/491714.
8
Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S13-24. doi: 10.1086/491710.
9
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.
Clin Infect Dis. 2004 Jun 15;38(12):1700-5. doi: 10.1086/421092. Epub 2004 May 21.
10
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
J Clin Microbiol. 2004 Jun;42(6):2398-402. doi: 10.1128/JCM.42.6.2398-2402.2004.
Zotero 插件